GQ Bio Therapeutics Overview
- Year Founded
-
2012
- Status
-
Acquired/Merged
- Employees
-
20
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$30.6M
GQ Bio Therapeutics General Information
Description
Developer of a gene therapy vector platform (HCAd) designed to address challenges in the gene therapy field, including the transfer of large and multiple genes, efficient gene delivery, and large-scale manufacturability. The company's platform leverages AI to optimize the HCAd platform, including capsid engineering for tissue-specific gene therapy vectors, enabling the development of transformative treatments for chronic conditions such as osteoarthritis and intervertebral disc degeneration.
Contact Information
Website
www.gq-biotx.com(Operating Subsidiary)
Corporate Office
- Ballindamm 39
- 20095 Hamburg
- Germany
Corporate Office
- Ballindamm 39
- 20095 Hamburg
- Germany
GQ Bio Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 27-Feb-2025 | $30.6M | Completed | Generating Revenue | ||
| 4. Grant | 26-Jan-2021 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 26-Jan-2021 | Completed | Generating Revenue | |||
| 2. Grant | 15-Dec-2016 | $100K | $1.55M | Completed | Generating Revenue | |
| 1. Seed Round | 12-Nov-2012 | $1.55M | $1.55M | Completed | Generating Revenue |
GQ Bio Therapeutics Patents
GQ Bio Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024182549-A1 | Compositions and methods for improved adenoviral- based gene therapy utilizing corticosteroid treatment | Inactive | 02-Mar-2023 | ||
| US-20260174905-A1 | Compositions and methods for improved adenoviral-based gene therapy utilizing corticosteroid treatment | Pending | 02-Mar-2023 |
GQ Bio Therapeutics Signals
GQ Bio Therapeutics Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| High-Tech Gründerfonds | Venture Capital | Minority | ||
| Innovationsstarter | Accelerator/Incubator | Minority | ||
| Investitionsbank des Landes Brandenburg | Investment Bank | |||
| Merck Biopharma | Corporation | |||
| Noshaq | Venture Capital | Minority |
GQ Bio Therapeutics FAQs
-
When was GQ Bio Therapeutics founded?
GQ Bio Therapeutics was founded in 2012.
-
Where is GQ Bio Therapeutics headquartered?
GQ Bio Therapeutics is headquartered in Hamburg, Germany.
-
What is the size of GQ Bio Therapeutics?
GQ Bio Therapeutics has 20 total employees.
-
What industry is GQ Bio Therapeutics in?
GQ Bio Therapeutics’s primary industry is Drug Discovery.
-
Is GQ Bio Therapeutics a private or public company?
GQ Bio Therapeutics is a Private company.
-
What is the current valuation of GQ Bio Therapeutics?
The current valuation of GQ Bio Therapeutics is .
-
What is GQ Bio Therapeutics’s current revenue?
The current revenue for GQ Bio Therapeutics is .
-
How much funding has GQ Bio Therapeutics raised over time?
GQ Bio Therapeutics has raised $11.5M.
-
Who are GQ Bio Therapeutics’s investors?
High-Tech Gründerfonds, Innovationsstarter, Investitionsbank des Landes Brandenburg, Merck Biopharma, and Noshaq are 5 of 6 investors who have invested in GQ Bio Therapeutics.
-
When was GQ Bio Therapeutics acquired?
GQ Bio Therapeutics was acquired on 27-Feb-2025.
-
Who acquired GQ Bio Therapeutics?
GQ Bio Therapeutics was acquired by Pacira BioSciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process